Romidepsin

罗米地辛

Report date: 2023/05/05 17:09:10
NME

Base Information

Drug NameRomidepsin
Drug Alias Name洛米迪星DepsipeptideRomidepsinum罗咪酯肽罗米地新 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsEsophageal adenocarcinomaSkin MelanomaSolid tumours +[94] 
Global Approved IndicationsLymphoma, T-Cell, PeripheralLymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/11/05
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentCelgene CorpBristol-Myers Squibb Company
Inactive CompaniesUniversity of Texas Southwestern Medical CenterCelgene Europe LtdLudwig Institute For Cancer Research +[7] 
Active IndicationsPheochromocytomaLymphoma, T-Cell, PeripheralLymphoma
Inactive IndicationsEsophageal adenocarcinomaSkin MelanomaSolid tumours +[91] 

Other Information

ATC CodeL01XH02
Related LinksWikipediaDrugBankKEGG